Form 4: Altimmune CEO Reports Stock Transactions Following RSU Vesting and ESPP Purchase

Altimmune's CEO, Vipin K. Garg, reported multiple transactions involving the company's stock, including the vesting of restricted stock units and purchases through the employee stock purchase plan.

Summary

• Altimmune CEO Vipin K. Garg reported several transactions involving the company's common stock.
• These transactions include the vesting of restricted stock units (RSUs) on January 30, 2025, February 1, 2025 and February 2, 2025.
• A portion of the vested shares were surrendered to cover taxes associated with the vesting.
• The CEO also purchased shares through the company's Employee Stock Purchase Plan (ESPP) on January 31, 2025.
• The ESPP purchase was based on 85% of the closing price of the company's stock on August 1, 2024.
• The reported transactions resulted in a net increase in the CEO's holdings of Altimmune common stock.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation and employee stock purchase plans, which is generally neutral to positive. The CEO's participation in the ESPP suggests confidence in the company.

Positives

• The CEO's participation in the ESPP demonstrates confidence in the company's future.
• The vesting of RSUs is a standard form of compensation for executives.

Negatives

• The surrender of shares to cover taxes reduces the net increase in the CEO's holdings.

Risks

• Fluctuations in the stock price could impact the value of the CEO's holdings.
• The vesting of RSUs is subject to the CEO's continued service with the company.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders, such as the CEO, make transactions in the company's stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• The vesting of restricted stock units and participation in employee stock purchase plans are common forms of compensation for executives in the biotechnology industry.
• The reporting of these transactions via SEC Form 4 is a standard practice for publicly traded companies, ensuring transparency and compliance with securities regulations.
• The specific vesting schedules and ESPP terms are typical for companies of Altimmune's size and stage of development.

Stakeholder Impact

• The transactions have a minor positive impact on shareholders as they demonstrate the CEO's confidence in the company.
• The vesting of RSUs and ESPP participation are positive for the CEO as they are part of their compensation package.

Key Dates

Keywords

Altimmune, Vipin K. Garg, stock transactions, restricted stock units, RSU, employee stock purchase plan, ESPP, insider trading, SEC Form 4